

Complement as a Therapeutic Target in Systemic Autoimmune Diseases

María Galindo-Izquierdo*, José Luis Pablos Alvarez

Servicio de Reumatología, Instituto de Investigación 12 de Octubre, Universidad Complutense de Madrid, 28040 Madrid, Spain

* Author to whom correspondence should be addressed.

Cells 2021, 10(1), 148; <https://doi.org/10.3390/cells10010148>

Abstract

The complement system (CS) includes more than 50 proteins and its main function is to recognize and protect against foreign or damaged molecular components. Other homeostatic functions of CS are the elimination of apoptotic debris, neurological development, and the control of adaptive immune responses. Pathological activation plays prominent roles in the pathogenesis of most autoimmune diseases such as systemic lupus erythematosus, anti-phospholipid syndrome, rheumatoid arthritis, dermatomyositis, and ANCA-associated vasculitis. In this review, we will review the main rheumatologic autoimmune processes in which complement plays a pathogenic role and its potential relevance as a therapeutic target.

<https://www.mdpi.com/2073-4409/10/1/148/htm>

Complement Products List

| Cat# | Description | Cat# | Description |
|------|---------------------------------------|--------|--------------------------------------|
| A006 | MicroVue iC3b EIA (For C3 activation) | A035 | MicroVue C4a Fragment EIA |
| A009 | MicroVue C4d Fragment EIA | A039 | MicroVue Factor H EIA |
| A020 | MicroVue SC5b-9 Plus EIA | A041 | MicroVue Factor I EIA |
| A021 | MicroVue C5a EIA | 20261 | MicroVue Pan-Specific C3 Reagent Kit |
| A031 | MicroVue C3a Plus EIA | BP029 | MBL Oligomer EIA |
| A033 | MicroVue Ba Fragment EIA | TE1038 | Mouse C3a ELISA |

| Cat# | Description | Cat# | Description |
|------|-------------------------------|------|---|
| A201 | Anti-human C1q | A231 | Anti-human Factor I#2 |
| A203 | Anti-human C3a | A233 | Anti-human Factor P#1 |
| A205 | Anti-human C3 (C3c) | A235 | Anti-human Factor P#2 |
| A207 | Anti-human C3 (C3d) | A237 | Anti-human S-Protein (vitronectin) |
| A209 | Anti-human iC3b (neoantigen) | A239 | Anti-human SC5b-9 (TCC neoantigen) |
| A211 | Anti-human C4 (C4c) | A241 | Anti-human Clusterin (SP40, 40 and Apo J) |
| A213 | Anti-human C4 (C4d) | A247 | Anti-human Factor I#1 |
| A215 | Anti-human C4 binding protein | A249 | Anti-human C8 |
| A217 | Anti-human C5 | A250 | Anti-human C3d |
| A219 | Anti-human C6 | A251 | Anti-human C4d (neoantigen) |
| A221 | Anti-human C7 | A252 | Anti-human Bb (neoantigen) |
| A223 | Anti-human C9 | A253 | Anti-human C4 (C4d) |
| A225 | Anti-human Factor B (Ba) | A254 | Anti-human Factor H#2 |
| A227 | Anti-human Factor B (Bb) | A255 | Anti-human Factor H#3 |
| A229 | Anti-human Factor H#1 | | |